Use of Perampanel for Refractory Seizures in Pediatric Patients

Marcia L. Buck, PharmD, FCCP, FPPAG


Pediatr Pharm. 2016;22(1) 

In This Article


Perampanel is a unique alternative to traditional antiseizure drugs for adolescents with refractory seizures. It was approved by the Food and Drug Administration (FDA) on October 22, 2012 for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients 12 years of age and older. On June 19, 2015, the FDA extended the approval to include the treatment of primary generalized tonic-clonic seizures.[1–3] Several recent papers have focused on the efficacy and safety of perampanel in children and adolescents, adding to our understanding of this drug in the pediatric population.